These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12150195)

  • 1. Immunoprophylaxis for respiratory syncytial virus.
    Sánchez PJ
    Pediatr Infect Dis J; 2002 May; 21(5):473-8. PubMed ID: 12150195
    [No Abstract]   [Full Text] [Related]  

  • 2. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
    [No Abstract]   [Full Text] [Related]  

  • 3. Case management for pediatric respiratory syncytial virus outcomes.
    Deming LM
    Case Manager; 2002; 13(4):72-4. PubMed ID: 12131912
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
    Kamal-Bahl S; Doshi J; Campbell J
    Arch Pediatr Adolesc Med; 2002 Oct; 156(10):1034-41. PubMed ID: 12361451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus: concerns and control.
    McCarthy CA; Hall CB
    Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who shall not receive palivizumab?
    Brunvand L; Lindemann R; Grøgaard J
    Pediatrics; 2000 Oct; 106(4):866. PubMed ID: 11183179
    [No Abstract]   [Full Text] [Related]  

  • 10. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

  • 11. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
    Greenough A
    Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?
    Klassen TP
    Arch Pediatr Adolesc Med; 2002 Dec; 156(12):1180-1. PubMed ID: 12444825
    [No Abstract]   [Full Text] [Related]  

  • 13. Appropriate use of palivizumb (Synagis).
    Graham LM; Lesnick B
    Pediatr Pulmonol Suppl; 2004; 26():156-7. PubMed ID: 15029637
    [No Abstract]   [Full Text] [Related]  

  • 14. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric case management for respiratory syncytial virus outcomes.
    Rieve JA
    Case Manager; 2002; 13(2):32-4. PubMed ID: 11901367
    [No Abstract]   [Full Text] [Related]  

  • 16. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed?].
    Salas Hernández S
    An Pediatr (Barc); 2004 Jan; 60(1):87-8. PubMed ID: 14718137
    [No Abstract]   [Full Text] [Related]  

  • 18. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
    Suresh S; Schilling S; Dakin C; Harris MA
    J Paediatr Child Health; 2003 Nov; 39(8):637. PubMed ID: 14629536
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
    Meissner HC; Rennels MB; Pickering LK; Hall CB
    Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.